Aromatase inhibitors and bone health in women with breast cancer.
about
Bisphosphonates for prevention of bone loss in women with early breast cancerPrevention and treatment of bone fragility in cancer patientThe National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trialHeel ultrasound can assess maintenance of bone mass in women with breast cancer.Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell linesExercise improves body fat, lean mass, and bone mass in breast cancer survivorsThe effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.Effects of flaxseed lignan and oil on bone health of breast-tumor-bearing mice treated with or without tamoxifen.Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.Overuse of short-interval bone densitometry: assessing rates of low-value care.Bone health history in breast cancer patients on aromatase inhibitors.AIs: implications for fractures in perimenopausal women with breast cancer.Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.Clinical utility of exemestane in the treatment of breast cancerCharacterization of the weak estrogen receptor alpha agonistic activity of exemestane.The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerAssociations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trialThe Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.Some musculo-skeletal sequelae in cancer survivors.Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy VolunteersUpdate on the use of letrozole in breast cancer.Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.Progression of endocrine therapies for breast cancer: where are we headed?Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.The expanding use of third-generation aromatase inhibitors: what the general internist needs to knowPharmacogenomics of endocrine therapy in breast cancer.Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trialHow do I follow patients with early breast cancer after completing adjuvant therapy.Safety of aromatase inhibitor therapy in breast cancer.Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis.Multidisciplinary Approach for Bone Metastasis: A Review.
P2860
Q24240547-174F3CD5-A92A-4722-AFA1-FD1310D04763Q26775765-B185C85D-CA1A-4AA1-BFBE-E1AA92EA0EAFQ28217652-8547B672-991A-4C5D-B77C-A872E10FD762Q30383587-83110898-B85A-4E06-880F-360B29EC2D92Q33630784-B016F09A-F624-4A9C-9290-C0B39F5FE4CCQ33718304-7CA4D2AB-3F53-4427-8307-2026D5BBEBB2Q33738327-700D8DA6-42B9-458B-BCB8-004D1FC67E40Q33802932-5E5A63B3-BBFD-4661-BA3F-ACD0750B3822Q33889613-F48848B4-C11A-45AF-BD24-F8A50B1D103EQ34194379-23E704A3-603A-4A0C-ABDB-A1DAB3F7F5F8Q34410750-974D4645-E313-468F-BDFD-CF31490C9FCDQ34421028-F13DB3C5-A52D-4625-BE92-4BD71C344FB9Q34526604-126039D9-9F13-4F3C-95B2-A8A89FFD6DC2Q35058455-E4B17787-5596-4259-AC78-6592EAB91505Q35155647-E2328961-A74B-48D9-90A7-41EE04C36500Q35683807-5030254B-995C-470D-9034-54162603CA9EQ36415607-12FF8F90-623E-47A0-8598-331855378FD0Q36432163-3B0530FC-3A7B-47E4-834A-D3667D71A347Q36728379-882E6F01-D0D5-4049-A488-3D863AAAD455Q36729512-43C1D01E-49C7-4A63-9756-DD41C5FAB683Q36817100-97C267D9-3BB3-4654-AB05-93ACA1A1C5F3Q36819570-2F4B3A76-BF85-4091-A84B-22EBF26AD84EQ36940755-B217B540-E6BD-463C-8B2A-9C92A96873ACQ36967277-8F57ABB8-2BCE-4F6E-B0CC-DA216DE7CC4AQ36976210-32DF4C56-FC06-40E5-A749-413F39A213D9Q37004695-2DC4A694-D7FC-4E6F-9F54-E383D53BE2C2Q37123420-97F3120B-0471-4F09-9655-CF4025E2004FQ37316233-EF0B832E-B404-4710-B88D-82DDD3878098Q37390076-FD08FEC0-EA6F-4AAB-8202-564B71C53E37Q37588045-5185A637-774A-44CC-8C1F-2777F3AADA1EQ37712223-465601B6-8AD0-45A4-A344-ABFC595D1917Q38172001-58EC3E04-104D-49D5-A0D9-EE4B324D84B1Q38522924-58D596F1-817D-4522-8E57-4B7D5001E90CQ38670417-C6D5DA39-31C9-4647-B75B-23E7963C661FQ43567721-57C2BF31-7106-4F78-BD57-E0EBE537B4D5Q47652004-61BD7CCF-49DC-4FC2-9AE5-0A15C55B3ADBQ49718126-E3BCDF2A-1E4E-421D-89B7-ED83F7485FEDQ53136867-AAD1A7B5-A04B-49FE-8DB5-62F802AE2BBBQ54975223-C27B7B06-A148-4BEB-88ED-DFCE1FC86FBDQ55473357-794B5A4E-C1D6-42E1-8D7D-6ED9B9A5340F
P2860
Aromatase inhibitors and bone health in women with breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Aromatase inhibitors and bone health in women with breast cancer.
@ast
Aromatase inhibitors and bone health in women with breast cancer.
@en
type
label
Aromatase inhibitors and bone health in women with breast cancer.
@ast
Aromatase inhibitors and bone health in women with breast cancer.
@en
prefLabel
Aromatase inhibitors and bone health in women with breast cancer.
@ast
Aromatase inhibitors and bone health in women with breast cancer.
@en
P356
P1476
Aromatase inhibitors and bone health in women with breast cancer.
@en
P2093
Amy Jo Chien
Paul E Goss
P304
P356
10.1200/JCO.2006.07.5382
P407
P577
2006-11-01T00:00:00Z